Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2021 | 2024 | 2025 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $1.88B | $1.84B |
| Cost of revenue | $0 | $0 | $1.38B | $1.36B |
| Gross profit | $0 | $0 | $493.7M | $474.6M |
| Gross margin | — | — | 26.3% | 25.9% |
| R&D | $0 | $0 | $0 | $0 |
| Operating income | −$1.9M | −$3.4M | $18.6M | $23.2M |
| EBITDA | $317.9K | −$3.4M | −$49.8M | $28.7M |
| Net income | $8.9K | −$10.3M | −$62.1M | −$80.3M |
| Net margin | — | — | -3.3% | -4.4% |
| EPS (diluted) | 0.00 | -3.47 | -1.96 | -2.55 |
Annual figures · source: Financial Modeling Prep
No one on the platform currently holds BRPM.
No tracked institution reports a position in BRPM as of their last filing.
No one on the platform has traded BRPM yet.
| +48.26% |
| $1.1B |
| — |
| HUMAHumacyte, Inc. | $0.80 | +12.74% | $134M | — |
| ITHXITHAX Acquisition Corp. | $10.13 | -27.59% | $851M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.